发明名称 |
Means for treating prostate hypertrophy and prostate cancer |
摘要 |
A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs Cetrorelix alone or in combination with alpha -reductase inhibitors or alpha -receptor blocking agents. The regimen reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range Cetrorelix is administered at dosages between 0,5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0,30 mg/kg body weight per week or at levels of about 25 to 120 mg of Cetrorelix per month or 0.376 mg kg to 1.71 mg/kg per month Cetrorelix can be administered with alpha -reductase inhibitors or alpha -receptor blocking agents.
|
申请公布号 |
US6054432(A) |
申请公布日期 |
2000.04.25 |
申请号 |
US19970908198 |
申请日期 |
1997.08.07 |
申请人 |
ASTA MEDICA AKTIENGESELLSCHAFT |
发明人 |
ENGEL, JUERGEN;REISSMANN, THOMAS;RIETHMUELLER-WINZEN, HILDE;RAWERT, JUERGEN |
分类号 |
A61P5/24;A61K31/495;A61K38/04;A61K38/09;A61K45/00;A61K45/06;A61P13/08;A61P35/00;(IPC1-7):A61K38/00 |
主分类号 |
A61P5/24 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|